ps://www.youtube.com/watch?v=Rlfs6hthwGo, range: {length:18,start:172}, type: lin

k}],identifier: anf-body-

49,“inlineTextStyles:[{range: {length:234,start:0},textsStyle: anf-ts-

i}, {range™: {length:234,start:0},textStyle: anf-ts-1}],layout:default-
body, role:body,text:Since Labor Day, Mr. Menendezad€™s campaign, perhaps ina

sign of vulnerability, has aggressively ramped up its advertising campaign, with a
majority of the political attacks accusing Mr. Hugin of raising drug prices to maximize
profits.,type:text}, {identifier: anf-body-
50, inlineTextStyles: [{range: {length:332,start:0},textsStyle: anf-ts-

i}, {range™: {length:332,start:0},textStyle:_anf-ts-1}],layout:default—
body, role:body, text:In 2017, after Mr. Hugin had stepped down as chief
executive and becom xecutive chairman, the company suffered two major setbacks in its
development pipeline: A drug it had hoped would be a breakthrough in treating Crohnda€™s
disease failed to outperform a control group and Otezla, a psoriasis drug, badly missed
sales expectations.,type™:text}, {additions™: [{URL:https://ir.celgene.com/press-—
releases/press-release-details/2017/Celgene-Provides-Update-on-GED-0301-mongersen
Inflammatory-Bowel-Diseas
Program/default.aspx, range: {length:39, start:21}, type™:link}, {URL:https://i
r.celgene.com/press-releases/press-release-details/2017/Celgene-Provides-Update-on-GED
0301-mongersen-Inflammatory-Bowel-Diseas
Program/default.aspx, range: {length:20,start:60}, type™:link}, {URL:https://w
ww.streetinsider.com/Analystt+Comments/Celgene+%28CELG%$29%3A+Pricet+tIncreases+Add+8ctiInti
T+-
+Suntrust/13411298 html, range: {length:64, start :161}, type™:link}], identifier

W

7 anf-body-
51, inlineTextStyles: [{range: {length:364,start:0},textsStyle: anf-ts-
i}, {range™: {length:364,start:0},textStyle:_anf-ts-1}],layout:default-

body, role:body, text:On the same day that Celgene announced it was scrapping the
Crohnaé€™s disease drug, it increased the price of Revlimid from $17,014 a bottle to
$18,546, according to a report by Yatin Suneja, an analyst who follows the industry. It
was the third price increase of Revlimid in 2017, representing a nearly 20 percent
price increase for the drug from the previous
year., type™:text}, {additions™: [{URL:https://d18rn0p25nwréd.cloudfront.net/CIK-
0000816284/ddd3eeae-cal0e-48c5-8132

54186f548874. pdf, range: {length:20,start:0},type™:link}],identifier: anf-
body-52, inlineTextStyles: [{range™:{length:156,start:0},textStyle: anf-ts-
i},{range™:{length:156,start:0},textStyle:_anf-ts-1}],layout:default-

body, role: body, text™:In financial filings, Celgene said these price hikes were a
main reason the drugaé&€™s net sales increased in 2017 by about $1.2 billion over the

previous year.,type:text}, {identifier: anf-body-
53,inlineTextStyles:[{range: {length:314,start:0},textstyle: anf-ts-

I}, {range™: {length:314,start:0},textStyle: anf-ts-1}],layout:default-—
body, role:body, text:Ronny Gal, a securities analyst at Sanford C. Bernstein &

Company who follows the pharmaceutical industry, said drug companies have generally
been dA€cetone deafa€ when it comes to raising the price of their monopoly products.
a€eCelgene clearly has been there, but has not been any worse than the main players, a4€

he said., type: text}, {identifier: anf-body-
54,inlineTextStyles: [{range: {length:412,start:0},textsStyle: anf-ts-
i}, {range™: {length:412,start:0},textStyle:_anf-ts-1}],layout:default—
body, role:body, text:The tactics can carry a human cost. Last year, Elaine

Kodish, a 76-year-old retir from Los Angeles, briefly stopped taking Revlimid after
her Medicare drug plan required she pay more than $450 a month for the drug that keeps
her multiple myeloma in check. Ms. Kodish said she bought stock in Celgene when sh
started taking Revlimid in 2016, as a way of supporting a company she believed was

keeping her alive.,type:text}, {identifier: anf-body-
55,inlineTextStyles: [{range: {length:364, start:0},textsStyle: anf-ts-

i}, {range™: {length:364,start:0},textStyle: anf-ts-1}],layout:default-
body, role:body, text:But after a series of price increases hav xposed her to

ballooning out-of-pocket costs 4€ she has since returned to taking Revlimid, which now
costs her about $785 per month 4€ she said she recently sold her stake. A€el4e™m
grateful to the drug companies, dond€™t get me wrong,a€ Ms. Kodish said. d€ceHowever,
they canaéd€™t be compensated on the backs of people who are
dying.a€,type:text}, {components: [{identifier: anf-heading6-
i,layout:related-coverage-heading, role: heading6, text: RELATED
COVERAGE, textStyle:related-

coverage, type: text}, {additions™: [{URL:https://www.nytimes.com/2017/07/25/healt
h/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer

HOUSE_OVERSIGHT_028421
